Merck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA ...
网页2023年4月7日 · Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer. KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. See additional selected KEYTRUDA indications in the U.S. after the Selected Important Safety Information.
FDA Approves First-Line Immunotherapy for Patients with MSI …
网页FDA approves Keytruda for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.
FDA Converts to Full Approval Indication for KEYTRUDA ... - Merck
网页2023年3月29日 · Non-Small Cell Lung Cancer. KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.
Merck Provides Update on Phase 3 KEYFORM-007 Trial Evaluating ...
网页5 天之前 · In the U.S., KEYTRUDA is approved for the treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer as determined by an FDA-approved test.
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
网页2020年12月2日 · Programmed death 1 (PD-1) blockade has emerged as highly effective therapy for patients with MSI-H–dMMR metastatic colorectal cancer that is refractory to standard chemotherapy combinations....
FDA approves pembrolizumab for first-line treatment of MSI …
网页On June 29, 2020, the Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck & Co.) for the first-line treatment of patients with unresectable or metastatic microsatellite...
FDA Grants Full Approval to Pembrolizumab for Select Patients
网页2023年3月29日 · The FDA has granted full approval to pembrolizumab (Keytruda) for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability–high (MSI-H) or mismatch...
Merck & Co's Keytruda gets new colorectal cancer use after month …
网页2024年9月17日 · It’s barely a month since Merck & Co unveiled trial results showing that cancer immunotherapy Keytruda (pembrolizumab) works in colorectal cancer patients with certain mutations, and the...
Advanced MSI-H/dMMR colorectal cancer (CRC) - KEYTRUDA
网页All of the 307 patients had advanced microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer that was previously untreated. 153 patients received 200 mg of KEYTRUDA every 3 weeks, and …
Keytruda as First-line Therapy for Certain Advanced Colorectal …
网页2020年7月1日 · The U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) as a first-line therapy for people with inoperable or metastatic colorectal cancer with specific genetic features that denote a high mutation rate.